Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL).
Purity:
>98.0%
CAS Number:
[1313206-42-6]
Target:
Drug-Linker Conjugates for ADC
* VAT and and shipping costs not included. Errors and price changes excepted
